Assessing the value of treatment for diabetes to patients, the healthcare system, and wider society: A case study on China

Assessing the value of treatment for diabetes to patients, the healthcare system, and wider society: A case study on China

Tim Wilsdon
Health Care | Life Sciences | Pharmaceuticals

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) commissioned Charles River Associates to review the evidence on the value of innovation for diabetes in middle-income countries (MICs) and test the extent to which the experience of these countries is aligned with the experience of high-income countries (HICs). The report provides an overview of the therapeutic and wider societal value of type-2 diabetes (T2D) medicines in China. China is the MIC with the largest number of people with T2D and has recognized T2D to be an escalating challenge. To read the report please click below.

Download PDF